Burns. II. Skin cover for full-thickness skin loss.

J. Reidy

DOI: https://doi.org/10.1097/00006534-195111000-00012

1951-05-01

British Medical Journal

Abstract:

What problem does this paper attempt to address?

Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates

Matthew Gagne,Barbara J. Flynn,Shayne F. Andrew,Josue Marquez,Dillon R. Flebbe,Anna Mychalowych,Evan Lamb,Meredith E. Davis-Gardner,Matthew R. Burnett,Leonid A. Serebryannyy,Bob C. Lin,Zohar E. Ziff,Erin Maule,Robin Carroll,Mursal Naisan,Yogita Jethmalani,Laurent Pessaint,John-Paul M. Todd,Nicole A. Doria-Rose,James Brett Case,Igor P. Dmitriev,Elena A. Kashentseva,Baoling Ying,Alan Dodson,Katelyn Kouneski,Sijy O'Dell,Bushra Wali,Madison Ellis,Sucheta Godbole,Farida Laboune,Amy R. Henry,I-Ting Teng,Danyi Wang,Lingshu Wang,Qiong Zhou,Serge Zouantchangadou,Alex Van Ry,Mark G. Lewis,Hanne Andersen,Peter D. Kwong,David T. Curiel,Mario Roederer,Martha C. Nason,Kathryn E. Foulds,Mehul S. Suthar,Michael S. Diamond,Daniel C. Douek,Robert A. Seder

DOI: https://doi.org/10.1038/s41590-024-01951-5

IF: 30.5

2024-09-04

Nature Immunology

Abstract:A mucosal route of vaccination could prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication at the site of infection and limit transmission. We compared protection against heterologous XBB.1.16 challenge in nonhuman primates (NHPs) ~5 months following intramuscular boosting with bivalent mRNA encoding WA1 and BA.5 spike proteins or mucosal boosting with a WA1–BA.5 bivalent chimpanzee adenoviral-vectored vaccine delivered by intranasal or aerosol device. NHPs boosted by either mucosal route had minimal virus replication in the nose and lungs, respectively. By contrast, protection by intramuscular mRNA was limited to the lower airways. The mucosally delivered vaccine elicited durable airway IgG and IgA responses and, unlike the intramuscular mRNA vaccine, induced spike-specific B cells in the lungs. IgG, IgA and T cell responses correlated with protection in the lungs, whereas mucosal IgA alone correlated with upper airway protection. This study highlights differential mucosal and serum correlates of protection and how mucosal vaccines can durably prevent infection against SARS-CoV-2.

immunology
Clinical applications of HLA testing.

W. Braun

Abstract:
Protection Against SARS-CoV-2 Infection by a Mucosal Vaccine in Rhesus Macaques.

Yongjun Sui,Jianping Li,Roushu Zhang,Sunaina Kiran Prabhu,Hanne Andersen,David Venzon,Anthony Cook,Renita Brown,Elyse Teow,Jason Velasco,Jack Greenhouse,Tammy Putman-Taylor,Tracey-Ann Campbell,Laurent Pessaint,Ian N. Moore,Laurel Lagenaur,Jim Talton,Matthew W. Breed,Josh Kramer,Kevin W. Bock,Mahnaz Minai,Bianca M. Nagata,Mark G. Lewis,Lai-Xi Wang,Jay A. Berzofsky

DOI: https://doi.org/10.1172/jci.insight.148494

IF: 9.4958

2021-01-01

JCI Insight

Abstract:Effective SARS-CoV-2 vaccines are urgently needed. Although most vaccine strategies have focused on systemic immunization, here we compared the protective efficacy of 2 adjuvanted subunit vaccines with spike protein S1: an intramuscularly primed/boosted vaccine and an intramuscularly primed/intranasally boosted mucosal vaccine in rhesus macaques. The intramuscular-alum–only vaccine induced robust binding and neutralizing antibody and persistent cellular immunity systemically and mucosally, whereas intranasal boosting with nanoparticles, including IL-15 and TLR agonists, elicited weaker T cell and Ab responses but higher dimeric IgA and IFN-α. Nevertheless, following SARS-CoV-2 challenge, neither group showed detectable subgenomic RNA in upper or lower respiratory tracts versus naive controls, indicating full protection against viral replication. Although mucosal and systemic protective mechanisms may differ, results demonstrate both vaccines can protect against respiratory SARS-CoV-2 exposure. In summary, we have demonstrated that the mucosal vaccine was safe after multiple doses and cleared the input virus more efficiently in the nasal cavity and thus may act as a potent complementary reinforcing boost for conventional systemic vaccines to provide overall better protection.
Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection

Mingxi Li,Jingao Guo,Shuaiyao Lu,Runhong Zhou,Hongyang Shi,Xuanling Shi,Lin Cheng,Qingtai Liang,Hongqi Liu,Pui Wang,Nan Wang,Yifeng Wang,Lili Fu,Man Xing,Ruoke Wang,Bin Ju,Li Liu,Siu-Ying Lau,Wenxu Jia,Xin Tong,Lin Yuan,Yong Guo,Hai Qi,Qi Zhang,Zhen Huang,Honglin Chen,Zheng Zhang,Zhiwei Chen,Xiaozhong Peng,Dongming Zhou,Linqi Zhang

DOI: https://doi.org/10.3389/fimmu.2021.697074

IF: 7.3

2021-06-28

Frontiers in Immunology

Abstract:The development of a safe and effective vaccine against SARS-CoV-2, the causative agent of pandemic coronavirus disease-2019 (COVID-19), is a global priority. Here, we aim to develop novel SARS-CoV-2 vaccines based on a derivative of less commonly used rare adenovirus serotype AdC68 vector. Three vaccine candidates were constructed expressing either the full-length spike (AdC68-19S) or receptor-binding domain (RBD) with two different signal sequences (AdC68-19RBD and AdC68-19RBDs). Single-dose intramuscular immunization induced robust and sustained binding and neutralizing antibody responses in BALB/c mice up to 40 weeks after immunization, with AdC68-19S being superior to AdC68-19RBD and AdC68-19RBDs. Importantly, immunization with AdC68-19S induced protective immunity against high-dose challenge with live SARS-CoV-2 in a golden Syrian hamster model of SARS-CoV-2 infection. Vaccinated animals demonstrated dramatic decreases in viral RNA copies and infectious virus in the lungs, as well as reduced lung pathology compared to the control animals. Similar protective effects were also found in rhesus macaques. Taken together, these results confirm that AdC68-19S can induce protective immune responses in experimental animals, meriting further development toward a human vaccine against SARS-CoV-2.

immunology
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease

Sham Nambulli,Nicolas Escriou,Linda J Rennick,Matthew J Demers,Natasha L Tilston-Lunel,Anita K McElroy,Dominique J Barbeau,Nicholas A Crossland,Ryan M Hoehl,Sabrina Schrauf,Alexander G White,H Jacob Borish,Jaime A Tomko,Lonnie J Frye,Charles A Scanga,JoAnne L Flynn,Annette Martin,Christiane Gerke,Amy L Hartman,W Paul Duprex

DOI: https://doi.org/10.1128/jvi.01762-23

2024-05-14

Abstract:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 and is responsible for the largest human pandemic in 100 years. Thirty-four vaccines are currently approved for use worldwide, and approximately 67% of the world population has received a complete primary series of one, yet countries are dealing with new waves of infections, variant viruses continue to emerge, and breakthrough infections are frequent secondary to waning immunity. Here, we evaluate a measles virus (MV)-vectored vaccine expressing a stabilized prefusion SARS-CoV-2 spike (S) protein (MV-ATU3-S2PΔF2A; V591) with demonstrated immunogenicity in mouse models (see companion article [J. Brunet, Z. Choucha, M. Gransagne, H. Tabbal, M.-W. Ku et al., J Virol 98:e01693-23, 2024, https://doi.org/10.1128/jvi.01693-23]) in an established African green monkey model of disease. Animals were vaccinated with V591 or the control vaccine (an equivalent MV-vectored vaccine with an irrelevant antigen) intramuscularly using a prime/boost schedule, followed by challenge with an early pandemic isolate of SARS-CoV-2 at 56 days post-vaccination. Pre-challenge, only V591-vaccinated animals developed S-specific antibodies that had virus-neutralizing activity as well as S-specific T cells. Following the challenge, V591-vaccinated animals had lower infectious virus and viral (v) RNA loads in mucosal secretions and stopped shedding virus in these secretions earlier. vRNA loads were lower in these animals in respiratory and gastrointestinal tract tissues at necropsy. This correlated with a lower disease burden in the lungs as quantified by PET/CT at early and late time points post-challenge and by pathological analysis at necropsy.IMPORTANCESevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the largest human pandemic in 100 years. Even though vaccines are currently available, countries are dealing with new waves of infections, variant viruses continue to emerge, breakthrough infections are frequent, and vaccine hesitancy persists. This study uses a safe and effective measles vaccine as a platform for vaccination against SARS-CoV-2. The candidate vaccine was used to vaccinate African green monkeys (AGMs). All vaccinated AGMs developed robust antigen-specific immune responses. After challenge, these AGMs produced less virus in mucosal secretions, for a shorter period, and had a reduced disease burden in the lungs compared to control animals. At necropsy, lower levels of viral RNA were detected in tissue samples from vaccinated animals, and the lungs of these animals lacked the histologic hallmarks of SARS-CoV-2 disease observed exclusively in the control AGMs.
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial

Stefania Capone,Francesco M Fusco,Stefano Milleri,Silvio Borrè,Sergio Carbonara,Sergio Lo Caputo,Sebastiano Leone,Giovanni Gori,Paolo Maggi,Antonio Cascio,Miriam Lichtner,Roberto Cauda,Sarah Dal Zoppo,Maria V Cossu,Andrea Gori,Silvia Roda,Paola Confalonieri,Stefano Bonora,Gabriele Missale,Mauro Codeluppi,Ivano Mezzaroma,Serena Capici,Emanuele Pontali,Marco Libanore,Augusta Diani,Simone Lanini,Simone Battella,Alessandra M Contino,Eva Piano Mortari,Francesco Genova,Gessica Parente,Rosella Dragonetti,Stefano Colloca,Luigi Visani,Claudio Iannacone,Rita Carsetti,Antonella Folgori,Roberto Camerini,COVITAR study group,Luigi Ziviani,Feliciana Malescio,Irene Turrini,Rita Lawlor,Annamaria Romano,Mariagrazia Nunziata,Salvatore Armato,Nicole Mazzeo,Maria Aurora Carleo,Chiara Dell'Isola,Raffaella Pisapia,Agostina Pontarelli,Andrea Olivani,Sara Grasselli,Diletta Laccabue,Maria Cristina Leoni,Franco Paolillo,Annalisa Mancini,Barbara Ruaro,Marco Confalonieri,Francesco Salton,Giulia Mancarella,Raffaella Marocco,Margherita De Masi,Valeria Belvisi,Silvia Lamonica,Antonella Cingolani,Cristina Seguiti,Paola Brambilla,Alice Ferraresi,Matteo Lupi,Serena Ludovisi,Giulia Renisi,Roberta Massafra,Martina Pellicciotta,Luciana Armiento,Stefania Vimercati,Mariagrazia Piacenza,Paolo Bonfanti,Paola Columpsi,Marina Elena Cazzaniga,Cristina Rovelli,Mariaelena Ceresini,Letizia Previtali,Laura Trentini,Chiara Alcantarini,Walter Rugge,Stefano Biffi,Federica Poletti,Roberto Rostagno,Roberta Moglia,Ferdinando De Negri,Elisabetta Fini,Alice Cangialosi,Serena Rita Bruno,Marianna Rizzo,Mariangela Niglio,Anna Dello Stritto,Alfredo Matano,Arnolfo Petruzziello,Pietro Valsecchi,Teresa Pieri,Mauro Altamura,Angela Calamo,Anna Giannelli,Stefania Menolascina,Silvia Di Bari,Vera Mauro,Raissa Aronica,Daniela Segala,Rosario Cultrera,Laura Sighinolfi,Michelle Abbott,Andrea Gizzi,Federica Guida Marascia,Giacomo Valenti,Marcello Feasi,Nicoletta Bobbio,Filippo Del Puente,Alfredo Nicosia,Martina Frascà,Miriam Mazzoleni,Nadia Garofalo,Virginia Ammendola,Fabiana Grazioli,Federico Napolitano,Alessandra Vitelli,Valentina Marcellini

DOI: https://doi.org/10.1016/j.xcrm.2023.101084

2023-06-20

Abstract:The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and heterologous immunization approaches implemented worldwide for booster doses call for diversified vaccine portfolios. GRAd-COV2 is a gorilla adenovirus-based COVID-19 vaccine candidate encoding prefusion-stabilized spike. The safety and immunogenicity of GRAd-COV2 is evaluated in a dose- and regimen-finding phase 2 trial (COVITAR study, ClinicalTrials.gov: NCT04791423) whereby 917 eligible participants are randomized to receive a single intramuscular GRAd-COV2 administration followed by placebo, or two vaccine injections, or two doses of placebo, spaced over 3 weeks. Here, we report that GRAd-COV2 is well tolerated and induces robust immune responses after a single immunization; a second administration increases binding and neutralizing antibody titers. Potent, variant of concern (VOC) cross-reactive spike-specific T cell response peaks after the first dose and is characterized by high frequencies of CD8s. T cells maintain immediate effector functions and high proliferative potential over time. Thus, GRAd vector is a valuable platform for genetic vaccine development, especially when robust CD8 response is needed.
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts Against SARS-CoV-2

Ahmed O. Hassan,Natasha M. Kafai,Igor P. Dmitriev,Julie M. Fox,Brittany K. Smith,Ian B. Harvey,Rita E. Chen,Emma S. Winkler,Alex W. Wessel,James Brett Case,Elena Kashentseva,Broc T. McCune,Adam L. Bailey,Haiyan Zhao,Laura A. VanBlargan,Ya-Nan Dai,Meisheng Ma,Lucas J. Adams,Swathi Shrihari,Jonathan E. Danis,Lisa E. Gralinski,Yixuan J. Hou,Alexandra Schaefer,Arthur S. Kim,Shamus P. Keeler,Daniela Weiskopf,Ralph S. Baric,Michael J. Holtzman,Daved H. Fremont,David T. Curiel,Michael S. Diamond

DOI: https://doi.org/10.1016/j.cell.2020.08.026

2020-01-01

Abstract:The coronavirus disease 2019 pandemic has made deployment of an effective vaccine a global health priority. We evaluated the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a prefusion stabilized spike protein (ChAd-SARS-CoV-2-S) in challenge studies with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor. Intramuscular dosing of ChAd-SARS-CoV-2-S induces robust systemic humoral and cell-mediated immune responses and protects against lung infection, inflammation, and pathology but does not confer sterilizing immunity, as evidenced by detection of viral RNA and induction of anti-nucleoprotein antibodies after SARS-CoV-2 challenge. In contrast, a single intranasal dose of ChAd-SARS-CoV-2-S induces high levels of neutralizing antibodies, promotes systemic and mucosal immunoglobulin A (IgA) and T cell responses, and almost entirely prevents SARS-CoV-2 infection in both the upper and lower respiratory tracts. Intranasal administration of ChAd-SARS-CoV-2-S is a candidate for preventing SARS-CoV-2 infection and transmission and curtailing pandemic spread.
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Kizzmekia S Corbett,Barbara Flynn,Kathryn E Foulds,Joseph R Francica,Seyhan Boyoglu-Barnum,Anne P Werner,Britta Flach,Sarah O'Connell,Kevin W Bock,Mahnaz Minai,Bianca M Nagata,Hanne Andersen,David R Martinez,Amy T Noe,Naomi Douek,Mitzi M Donaldson,Nadesh N Nji,Gabriela S Alvarado,Darin K Edwards,Dillon R Flebbe,Evan Lamb,Nicole A Doria-Rose,Bob C Lin,Mark K Louder,Sijy O'Dell,Stephen D Schmidt,Emily Phung,Lauren A Chang,Christina Yap,John-Paul M Todd,Laurent Pessaint,Alex Van Ry,Shanai Browne,Jack Greenhouse,Tammy Putman-Taylor,Amanda Strasbaugh,Tracey-Ann Campbell,Anthony Cook,Alan Dodson,Katelyn Steingrebe,Wei Shi,Yi Zhang,Olubukola M Abiona,Lingshu Wang,Amarendra Pegu,Eun Sung Yang,Kwanyee Leung,Tongqing Zhou,I-Ting Teng,Alicia Widge,Ingelise Gordon,Laura Novik,Rebecca A Gillespie,Rebecca J Loomis,Juan I Moliva,Guillaume Stewart-Jones,Sunny Himansu,Wing-Pui Kong,Martha C Nason,Kaitlyn M Morabito,Tracy J Ruckwardt,Julie E Ledgerwood,Martin R Gaudinski,Peter D Kwong,John R Mascola,Andrea Carfi,Mark G Lewis,Ralph S Baric,Adrian McDermott,Ian N Moore,Nancy J Sullivan,Mario Roederer,Robert A Seder,Barney S Graham

DOI: https://doi.org/10.1056/NEJMoa2024671

2020-10-15

Abstract:Background: Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate in nonhuman primates. Methods: Nonhuman primates received 10 or 100 μg of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, or no vaccine. Antibody and T-cell responses were assessed before upper- and lower-airway challenge with SARS-CoV-2. Active viral replication and viral genomes in bronchoalveolar-lavage (BAL) fluid and nasal swab specimens were assessed by polymerase chain reaction, and histopathological analysis and viral quantification were performed on lung-tissue specimens. Results: The mRNA-1273 vaccine candidate induced antibody levels exceeding those in human convalescent-phase serum, with live-virus reciprocal 50% inhibitory dilution (ID50) geometric mean titers of 501 in the 10-μg dose group and 3481 in the 100-μg dose group. Vaccination induced type 1 helper T-cell (Th1)-biased CD4 T-cell responses and low or undetectable Th2 or CD8 T-cell responses. Viral replication was not detectable in BAL fluid by day 2 after challenge in seven of eight animals in both vaccinated groups. No viral replication was detectable in the nose of any of the eight animals in the 100-μg dose group by day 2 after challenge, and limited inflammation or detectable viral genome or antigen was noted in lungs of animals in either vaccine group. Conclusions: Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. (Funded by the National Institutes of Health and others.).
Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques

Nerea Zabaleta,Urja Bhatt,Cécile Hérate,Pauline Maisonnasse,Julio Sanmiguel,Cheikh Diop,Sofia Castore,Reynette Estelien,Dan Li,Nathalie Dereuddre-Bosquet,Mariangela Cavarelli,Anne-Sophie Gallouët,Quentin Pascal,Thibaut Naninck,Nidhal Kahlaoui,Julien Lemaitre,Francis Relouzat,Giuseppe Ronzitti,Hendrik Jan Thibaut,Emanuele Montomoli,Roger Le Grand,James M. Wilson,Luk H. Vandenberghe

DOI: https://doi.org/10.1016/j.ymthe.2022.05.007

IF: 12.91

2022-09-01

Molecular Therapy

Abstract:The COVID-19 pandemic continues to have devastating consequences on health and economy, even after the approval of safe and effective vaccines. Waning immunity, the emergence of variants of concern, breakthrough infections, and lack of global vaccine access and acceptance perpetuate the epidemic. Here, we demonstrate that a single injection of an adenoassociated virus (AAV)-based COVID-19 vaccine elicits at least 17-month-long neutralizing antibody responses in non-human primates at levels that were previously shown to protect from viral challenge. To improve the scalability of this durable vaccine candidate, we further optimized the vector design for greater potency at a reduced dose in mice and non-human primates. Finally, we show that the platform can be rapidly adapted to other variants of concern to robustly maintain immunogenicity and protect from challenge. In summary, we demonstrate this class of AAV can provide durable immunogenicity, provide protection at dose that is low and scalable, and be adapted readily to novel emerging vaccine antigens thus may provide a potent tool in the ongoing fight against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates

Nerea Zabaleta,Wenlong Dai,Urja Bhatt,Cécile Hérate,Pauline Maisonnasse,Julio Sanmiguel,Reynette Estelien,Cheikh Diop,Dawid Maciorowski,Nathalie Dereuddre-Bosquet,Mariangela Cavarelli,Anne-Sophie Gallouët,Thibaut Naninck,Nidhal Kahlaoui,Julien Lemaitre,Wenbin Qi,Elissa Hudspeth,Allison Cucalon,Dan Li,Maya Kim,Abigail Sheridan,Nadia Storm,Jared Feldman,Vanessa Contreras,Romain Marlin,Raphaël Ho Tsong Fang,Catherine Chapon,Sylvie van der Werf,Eric Zinn,Aisling Ryan,Ruchi Chauhan,Marion McGlynn,Brian Price,Anna Honko,Anthony Griffiths,Sam Yaghmour,Robert Hodge,Roger Le Grand,Jessica A. Chichester,Kristofer T. Michalson,Cecilia D. Dyer,M. Betina Pampena,James J. Knox,Regina C. LaRocque,Richelle C. Charles,Rebecca I. Johnson,Blake M. Hauser,Dione T. Kobayashi,Edward T. Ryan,Aaron G. Schmidt,Michael R. Betts,Mason W. Freeman,James M. Wilson,Luk H. Vandenberghe

DOI: https://doi.org/10.1016/j.chom.2021.08.002

2021-09-01

Abstract:The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 million deaths. To contain the pandemic, there is a continued need for safe vaccines that provide durable protection at low and scalable doses and can be deployed easily. Here, AAVCOVID-1, an adeno-associated viral (AAV), spike-gene-based vaccine candidate demonstrates potent immunogenicity in mouse and non-human primates following a single injection and confers complete protection from SARS-CoV-2 challenge in macaques. Peak neutralizing antibody titers are sustained at 1 year and complemented by functional memory T cell responses. The AAVCOVID vector has no relevant pre-existing immunity in humans and does not elicit cross-reactivity to common AAVs used in gene therapy. Vector genome persistence and expression wanes following injection. The single low-dose requirement, high-yield manufacturability, and 1-month stability for storage at room temperature may make this technology well suited to support effective immunization campaigns for emerging pathogens on a global scale.

microbiology,virology,parasitology
Mental retardation and memory for spatial locations.

Robert Jones,F. Vaughan,M. Roberts

DOI: https://doi.org/10.1352/0895-8017(2002)107<0099:MRAMFS>2.0.CO;2

2002-03-01

Abstract:Although memory for spatial location has been frequently investigated with mentally retarded populations, it is not clear that these individuals possess the same spatial memory skills as do their peers without mental retardation. We compared 30 persons with and 30 persons without mental retardation. Following either intentional or incidental learning, participants recalled and then relocated 16 objects on a matrix. The control group recalled more intentionally learned than incidentally learned material. The experimental group performed both tasks better after incidental learning than after intentional learning and scored as highly as the controls on incidental spatial memory. Results suggest that memory for spatial location is an automatic process and, to some extent at least, is not directly affected by the individual's level of intelligence.
A Next-Generation Adenoviral Vaccine Elicits Mucosal and Systemic Immunogenicity and Reduces Viral Shedding after SARS-CoV-2 Challenge in Nonhuman Primates

Sarah N. Tedjakusuma,Colin A. Lester,Elena D. Neuhaus,Emery G. Dora,Samanta Gutierrez,Molly R. Braun,Sean N. Tucker,Becca A. Flitter

DOI: https://doi.org/10.3390/vaccines12020132

2024-01-28

Vaccines

Abstract:As new SARS-CoV-2 variants continue to emerge and impact communities worldwide, next-generation vaccines that enhance protective mucosal immunity may have a significant impact on productive infection and transmission. We have developed recombinant non-replicating adenovirus serotype 5 (rAd5) vaccines delivered by mucosal administration that express both target antigen and a novel molecular adjuvant within the same cell. Here, we describe the immunogenicity of three unique SARS-CoV-2 rAd5 vaccine candidates and their efficacy following viral challenge in non-human primates (NHPs). Intranasal immunization with rAd5 vaccines expressing Wuhan, or Beta variant spike alone, or Wuhan spike and nucleocapsid elicited strong antigen-specific serum IgG and IgA with neutralizing activity against multiple variants of concern (VOC). Robust cross-reactive mucosal IgA was detected after a single administration of rAd5, which showed strong neutralizing activity against multiple VOC. Additionally, mucosal rAd5 vaccination increased spike-specific IFN-γ producing circulating T-cells. Upon Beta variant SARS-CoV-2 challenge, all the vaccinated NHPs exhibited significant reductions in viral load and infectious particle shedding in both the nasal passages and lower airways. These findings demonstrate that mucosal rAd5 immunization is highly immunogenic, confers protective cross-reactive antibody responses in the circulation and mucosa, and reduces viral load and shedding after SARS-CoV-2 challenge.

immunology,medicine, research & experimental
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Noe B. Mercado,Roland Zahn,Frank Wegmann,Carolin Loos,Abishek Chandrashekar,Jingyou Yu,Jinyan Liu,Lauren Peter,Katherine McMahan,Lisa H. Tostanoski,Xuan He,David R. Martinez,Lucy Rutten,Rinke Bos,Danielle van Manen,Jort Vellinga,Jerome Custers,Johannes P. Langedijk,Ted Kwaks,Mark J. G. Bakkers,David Zuijdgeest,Sietske K. Rosendahl Huber,Caroline Atyeo,Stephanie Fischinger,John S. Burke,Jared Feldman,Blake M. Hauser,Timothy M. Caradonna,Esther A. Bondzie,Gabriel Dagotto,Makda S. Gebre,Emily Hoffman,Catherine Jacob-Dolan,Marinela Kirilova,Zhenfeng Li,Zijin Lin,Shant H. Mahrokhian,Lori F. Maxfield,Felix Nampanya,Ramya Nityanandam,Joseph P. Nkolola,Shivani Patel,John D. Ventura,Kaylee Verrington,Huahua Wan,Laurent Pessaint,Alex Van Ry,Kelvin Blade,Amanda Strasbaugh,Mehtap Cabus,Renita Brown,Anthony Cook,Serge Zouantchangadou,Elyse Teow,Hanne Andersen,Mark G. Lewis,Yongfei Cai,Bing Chen,Aaron G. Schmidt,R. Keith Reeves,Ralph S. Baric,Douglas A. Lauffenburger,Galit Alter,Paul Stoffels,Mathai Mammen,Johan Van Hoof,Hanneke Schuitemaker,Dan H. Barouch

DOI: https://doi.org/10.1038/s41586-020-2607-z

IF: 64.8

2020-07-30

Nature

Abstract:A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic<sup>1–8</sup>. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in nonhuman primates. Fifty-two rhesus macaques were immunized with Ad26 vectors encoding S variants or sham control and were challenged with SARS-CoV-2 by the intranasal and intratracheal routes<sup>9,10</sup>. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs following SARS-CoV-2 challenge. Vaccine-elicited neutralizing antibody titres correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.

multidisciplinary sciences
Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection

Jiaojiao Liu,Kun Xu,Man Xing,Yue Zhuo,Jingao Guo,Meng Du,Qi Wang,Yaling An,Jinhe Li,Ping Gao,Yihan Wang,Furong He,Yingying Guo,Mingxi Li,Yuchao Zhang,Linqi Zhang,George F. Gao,Lianpan Dai,Dongming Zhou

DOI: https://doi.org/10.1038/s41421-021-00360-4

IF: 38.079

2021-12-01

Cell Discovery

Abstract:Abstract A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is urgently needed to tackle the COVID-19 global pandemic. Here, we describe the development of chimpanzee adenovirus serotypes 6 and 68 (AdC6 and AdC68) vector-based vaccine candidates expressing the full-length transmembrane spike glycoprotein. We assessed the vaccine immunogenicity, protective efficacy, and immune cell profiles using single-cell RNA sequencing in mice. Mice were vaccinated via the intramuscular route with the two vaccine candidates using prime-only regimens or heterologous prime-boost regimens. Both chimpanzee adenovirus-based vaccines elicited strong and long-term antibody and T cell responses, balanced Th1/Th2 cell responses, robust germinal center responses, and provided effective protection against SARS-CoV-2 infection in mouse lungs. Strikingly, we found that heterologous prime-boost immunization induced higher titers of protective antibodies, and more spike-specific memory CD8 + T cells in mice. Potent neutralizing antibodies produced against the highly transmissible SARS-CoV-2 variants B.1.1.7 lineage (also known as N501Y.V1) and B.1.351 lineage (also known as N501Y.V2) were detectable in mouse sera over 6 months after prime immunization. Our results demonstrate that the heterologous prime-boost strategy with chimpanzee adenovirus-based vaccines is promising for further development to prevent SARS-CoV-2 infection.

cell biology
A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates

M Gordon Joyce,Hannah A D King,Ines Elakhal-Naouar,Aslaa Ahmed,Kristina K Peachman,Camila Macedo Cincotta,Caroline Subra,Rita E Chen,Paul V Thomas,Wei-Hung Chen,Rajeshwer S Sankhala,Agnes Hajduczki,Elizabeth J Martinez,Caroline E Peterson,William C Chang,Misook Choe,Clayton Smith,Parker J Lee,Jarrett A Headley,Mekdi G Taddese,Hanne A Elyard,Anthony Cook,Alexander Anderson,Kathryn McGuckin Wuertz,Ming Dong,Isabella Swafford,James Brett Case,Jeffrey R Currier,Kerri G Lal,Sebastian Molnar,Manoj S Nair,Vincent Dussupt,Sharon P Daye,Xiankun Zeng,Erica K Barkei,Hilary M Staples,Kendra Alfson,Ricardo Carrion,Shelly J Krebs,Dominic Paquin-Proulx,Nicos Karasavva,Victoria R Polonis,Linda L Jagodzinski,Mihret F Amare,Sandhya Vasan,Paul T Scott,Yaoxing Huang,David D Ho,Natalia de Val,Michael S Diamond,Mark G Lewis,Mangala Rao,Gary R Matyas,Gregory D Gromowski,Sheila A Peel,Nelson L Michael,Diane L Bolton,Kayvon Modjarrad,M. Gordon Joyce,Hannah A. D. King,Kristina K. Peachman,Rita E. Chen,Paul V. Thomas,Rajeshwer S. Sankhala,Elizabeth J. Martinez,Caroline E. Peterson,William C. Chang,Parker J. Lee,Jarrett A. Headley,Mekdi G. Taddese,Hanne A. Elyard,Jeffrey R. Currier,Kerri G. Lal,Manoj S. Nair,Sharon P. Daye,Erica K. Barkei,Hilary M. Staples,Shelly J. Krebs,Victoria R. Polonis,Linda L. Jagodzinski,Mihret F. Amare,Paul T. Scott,David D. Ho,Michael S. Diamond,Mark G. Lewis,Gary R. Matyas,Gregory D. Gromowski,Sheila A. Peel,Nelson L. Michael,Diane L. Bolton

DOI: https://doi.org/10.1126/scitranslmed.abi5735

IF: 17.1

2022-02-16

Science Translational Medicine

Abstract:The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019. We developed and evaluated an adjuvanted SARS-CoV-2 spike ferritin nanoparticle (SpFN) vaccine in nonhuman primates. High-dose (50-μg) SpFN vaccine, given twice 28 days apart, induced a T helper cell 1 (T H 1)–biased CD4 T H response and elicited neutralizing antibodies against SARS-CoV-2 wild type and variants of concern, as well as against SARS-CoV-1. These potent humoral and cell-mediated immune responses translated into rapid elimination of replicating virus in the upper and lower airways and lung parenchyma of nonhuman primates after high-dose SARS-CoV-2 respiratory challenge. The immune response elicited by SpFN vaccination and resulting efficacy in nonhuman primates support the utility of SpFN as a vaccine candidate for SARS-causing betacoronaviruses.

cell biology,medicine, research & experimental
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine

Georgia Deliyannis,Chinn Yi Wong,Paula Ellenberg,Tim Smith,Marianne Gillard,Ester Lopez,Julie McAuley,Chee Wah Tan,Weiguang Zeng,Mason Littlejohn,Runhong Zhou,Jasper Fuk-Woo Chan,Richard Bowen,Elizabeth Vincan,Joseph Torresi,Katherine Kedzierska,Kanta Subbarao,Marc Pellegrini,Trent Munro,Terry Nolan,Steven Rockman,Nicholas A. Gherardin,Samantha L. Grimley,James P. Cooney,Samuel J. Redmond,Kathryn C. Davidson,Francesca L. Mordant,Jing J. Wang,Zhi-wei Chen,Airn E. Hartwig,Jason M. Mackenzie,Colin W. Pouton,Tom P. Gordon,Lin-fa Wang,Stephen J. Kent,Adam K. Wheatley,Sharon R. Lewin,Amy W. Chung,David C. Jackson,Damian F.J. Purcell,Dale I. Godfrey

DOI: https://doi.org/10.1016/j.ebiom.2023.104574

IF: 11.205

2023-06-01

EBioMedicine

Abstract:BACKGROUND: The SARS-CoV-2 global pandemic has fuelled the generation of vaccines at an unprecedented pace and scale. However, many challenges remain, including: the emergence of vaccine-resistant mutant viruses, vaccine stability during storage and transport, waning vaccine-induced immunity, and concerns about infrequent adverse events associated with existing vaccines.METHODS: We report on a protein subunit vaccine comprising the receptor-binding domain (RBD) of the ancestral SARS-CoV-2 spike protein, dimerised with an immunoglobulin IgG1 Fc domain. These were tested in conjunction with three different adjuvants: a TLR2 agonist R4-Pam2Cys, an NKT cell agonist glycolipid α-Galactosylceramide, or MF59® squalene oil-in-water adjuvant, using mice, rats and hamsters. We also developed an RBD-human IgG1 Fc vaccine with an RBD sequence of the immuno-evasive beta variant (N501Y, E484K, K417N). These vaccines were also tested as a heterologous third dose booster in mice, following priming with whole spike vaccine.FINDINGS: Each formulation of the RBD-Fc vaccines drove strong neutralising antibody (nAb) responses and provided durable and highly protective immunity against lower and upper airway infection in mouse models of COVID-19. The 'beta variant' RBD vaccine, combined with MF59® adjuvant, induced strong protection in mice against the beta strain as well as the ancestral strain. Furthermore, when used as a heterologous third dose booster, the RBD-Fc vaccines combined with MF59® increased titres of nAb against other variants including alpha, delta, delta+, gamma, lambda, mu, and omicron BA.1, BA.2 and BA.5.INTERPRETATION: These results demonstrated that an RBD-Fc protein subunit/MF59® adjuvanted vaccine can induce high levels of broadly reactive nAbs, including when used as a booster following prior immunisation of mice with whole ancestral-strain spike vaccines. This vaccine platform offers a potential approach to augment some of the currently approved vaccines in the face of emerging variants of concern, and it has now entered a phase I clinical trial.FUNDING: This work was supported by grants from the Medical Research Future Fund (MRFF) (2005846), The Jack Ma Foundation, National Health and Medical Research Council of Australia (NHMRC; 1113293) and Singapore National Medical Research Council (MOH-COVID19RF-003). Individual researchers were supported by an NHMRC Senior Principal Research Fellowship (1117766), NHMRC Investigator Awards (2008913 and 1173871), Australian Research Council Discovery Early Career Research Award (ARC DECRA; DE210100705) and philanthropic awards from IFM investors and the A2 Milk Company.

medicine, research & experimental
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Kizzmekia S Corbett,Martha C Nason,Britta Flach,Matthew Gagne,Sarah O'Connell,Timothy S Johnston,Shruti N Shah,Venkata Viswanadh Edara,Katharine Floyd,Lilin Lai,Charlene McDanal,Joseph R Francica,Barbara Flynn,Kai Wu,Angela Choi,Matthew Koch,Olubukola M Abiona,Anne P Werner,Juan I Moliva,Shayne F Andrew,Mitzi M Donaldson,Jonathan Fintzi,Dillon R Flebbe,Evan Lamb,Amy T Noe,Saule T Nurmukhambetova,Samantha J Provost,Anthony Cook,Alan Dodson,Andrew Faudree,Jack Greenhouse,Swagata Kar,Laurent Pessaint,Maciel Porto,Katelyn Steingrebe,Daniel Valentin,Serge Zouantcha,Kevin W Bock,Mahnaz Minai,Bianca M Nagata,Renee van de Wetering,Seyhan Boyoglu-Barnum,Kwanyee Leung,Wei Shi,Eun Sung Yang,Yi Zhang,John-Paul M Todd,Lingshu Wang,Gabriela S Alvarado,Hanne Andersen,Kathryn E Foulds,Darin K Edwards,John R Mascola,Ian N Moore,Mark G Lewis,Andrea Carfi,David Montefiori,Mehul S Suthar,Adrian McDermott,Mario Roederer,Nancy J Sullivan,Daniel C Douek,Barney S Graham,Robert A Seder,Kizzmekia S. Corbett,Martha C. Nason,Sarah O’Connell,Timothy S. Johnston,Shruti N. Shah,Joseph R. Francica,Olubukola M. Abiona,Anne P. Werner,Juan I. Moliva,Shayne F. Andrew,Mitzi M. Donaldson,Dillon R. Flebbe,Amy T. Noe,Saule T. Nurmukhambetova,Samantha J. Provost,Kevin W. Bock,Bianca M. Nagata,John-Paul M. Todd,Gabriela S. Alvarado,Kathryn E. Foulds,Darin K. Edwards,John R. Mascola,Ian N. Moore,Mark G. Lewis,Mehul S. Suthar,Nancy J. Sullivan,Daniel C. Douek,Barney S. Graham,Robert A. Seder

DOI: https://doi.org/10.1126/science.abj0299

IF: 56.9

2021-09-17

Science

Abstract:Antibodies dovetail with protection Immune correlates of protection are clinical end points used to gauge vaccine-induced immunogenicity and protection. Corbett et al . studied nonhuman primate (NHP) immune responses to various doses of the mRNA-1273 (Moderna) vaccine to provide a range of immune responses and protective outcomes. They determined that circulating spike protein–specific antibodies correlated with protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in the airways. Passively transferred NHP antibodies were sufficient to mediate protection against SARS-CoV-2 challenge in hamsters, emphasizing that antibodies are mechanistic correlates. Protection of the lower respiratory tract required lower serum antibody concentrations, possibly explaining why most current vaccines are highly effective against severe lower airway disease. The higher antibody threshold required for reducing upper airway infection has potential implications for boosting to limit transmission. —STS

multidisciplinary sciences
Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates

Stéphane Pillet,Prabhu S Arunachalam,Guadalupe Andreani,Nadia Golden,Jane Fontenot,Pyone Pyone Aye,Katharina Röltgen,Gabrielle Lehmicke,Philipe Gobeil,Charlotte Dubé,Sonia Trépanier,Nathalie Charland,Marc-André D'Aoust,Kasi Russell-Lodrigue,Christopher Monjure,Robert V Blair,Scott D Boyd,Rudolf P Bohm,Jay Rappaport,François Villinger,Nathalie Landry,Bali Pulendran,Brian J Ward

DOI: https://doi.org/10.1038/s41423-021-00809-2

Abstract:Although antivirals are important tools to control severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, effective vaccines are essential to control the current coronavirus disease 2019 (COVID-19) pandemic. Plant-derived virus-like particle (VLP) vaccine candidates have previously demonstrated immunogenicity and efficacy against influenza. Here, we report the immunogenicity and protection induced in rhesus macaques by intramuscular injections of a VLP bearing a SARS-CoV-2 spike protein (CoVLP) vaccine candidate formulated with or without Adjuvant System 03 (AS03) or cytidine-phospho-guanosine (CpG) 1018. Although a single dose of the unadjuvanted CoVLP vaccine candidate stimulated humoral and cell-mediated immune responses, booster immunization (at 28 days after priming) and adjuvant administration significantly improved both responses, with higher immunogenicity and protection provided by the AS03-adjuvanted CoVLP. Fifteen micrograms of CoVLP adjuvanted with AS03 induced a polyfunctional interleukin-2 (IL-2)-driven response and IL-4 expression in CD4 T cells. Animals were challenged by multiple routes (i.e., intratracheal, intranasal, and ocular) with a total viral dose of 106 plaque-forming units of SARS-CoV-2. Lower viral replication in nasal swabs and bronchoalveolar lavage fluid (BALF) as well as fewer SARS-CoV-2-infected cells and immune cell infiltrates in the lungs concomitant with reduced levels of proinflammatory cytokines and chemotactic factors in the BALF were observed in animals immunized with the CoVLP adjuvanted with AS03. No clinical, pathologic, or virologic evidence of vaccine-associated enhanced disease was observed in vaccinated animals. The CoVLP adjuvanted with AS03 was therefore selected for vaccine development and clinical trials.
A Single Intranasal or Intramuscular Immunization with Chimpanzee Adenovirus Vectored SARS-CoV-2 Vaccine Protects Against Pneumonia in Hamsters.

Traci L. Bricker,Tamarand L. Darling,Ahmed O. Hassan,Houda H. Harastani,Allison Soung,Xiaoping Jiang,Ya-Nan Dai,Haiyan Zhao,Lucas J. Adams,Michael J. Holtzman,Adam L. Bailey,James Brett Case,Daved H. Fremont,Robyn Klein,Michael S. Diamond,Adrianus C. M. Boon

DOI: https://doi.org/10.1016/j.celrep.2021.109400

2021-01-01

SSRN Electronic Journal

Abstract:The development of an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), is a global priority. Here, we compare the protective capacity of intranasal and intramuscular delivery of a chimpanzee adenovirus-vectored vaccine encoding a prefusion stabilized spike protein (chimpanzee adenovirus [ChAd]-SARS-CoV-2-S) in Golden Syrian hamsters. Although immunization with ChAd-SARS-CoV-2-S induces robust spike-protein-specific antibodies capable of neutralizing the virus, antibody levels in serum are higher in hamsters vaccinated by an intranasal compared to intramuscular route. Accordingly, against challenge with SARS-CoV-2, ChAd-SARS-CoV-2-S-immunized hamsters are protected against less weight loss and have reduced viral infection in nasal swabs and lungs, and reduced pathology and inflammatory gene expression in the lungs, compared to ChAd-control immunized hamsters. Intranasal immunization with ChAd-SARS-CoV-2-S provides superior protection against SARS-CoV-2 infection and inflammation in the upper respiratory tract. These findings support intranasal administration of the ChAd-SARS-CoV-2-S candidate vaccine to prevent SARS-CoV-2 infection, disease, and possibly transmission.
DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Jingyou Yu,Lisa H. Tostanoski,Lauren Peter,Noe B. Mercado,Katherine McMahan,Shant H. Mahrokhian,Joseph P. Nkolola,Jinyan Liu,Zhenfeng Li,Abishek Chandrashekar,David R. Martinez,Carolin Loos,Caroline Atyeo,Stephanie Fischinger,John S. Burke,Matthew D. Slein,Yuezhou Chen,Adam Zuiani,Felipe J. N. Lelis,Meghan Travers,Shaghayegh Habibi,Laurent Pessaint,Alex Van Ry,Kelvin Blade,Renita Brown,Anthony Cook,Brad Finneyfrock,Alan Dodson,Elyse Teow,Jason Velasco,Roland Zahn,Frank Wegmann,Esther A. Bondzie,Gabriel Dagotto,Makda S. Gebre,Xuan He,Catherine Jacob-Dolan,Marinela Kirilova,Nicole Kordana,Zijin Lin,Lori F. Maxfield,Felix Nampanya,Ramya Nityanandam,John D. Ventura,Huahua Wan,Yongfei Cai,Bing Chen,Aaron G. Schmidt,Duane R. Wesemann,Ralph S. Baric,Galit Alter,Hanne Andersen,Mark G. Lewis,Dan H. Barouch

DOI: https://doi.org/10.1126/science.abc6284

IF: 56.9

2020-05-20

Science

Abstract:The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers at levels comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. After vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log 10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with viral loads in sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates.

multidisciplinary sciences

Burns. II. Skin cover for full-thickness skin loss.

Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates

Clinical applications of HLA testing.

Protection Against SARS-CoV-2 Infection by a Mucosal Vaccine in Rhesus Macaques.

Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection

A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease

GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial

A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts Against SARS-CoV-2

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques

An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates

Mental retardation and memory for spatial locations.

A Next-Generation Adenoviral Vaccine Elicits Mucosal and Systemic Immunogenicity and Reduces Viral Shedding after SARS-CoV-2 Challenge in Nonhuman Primates

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection

A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates

A Single Intranasal or Intramuscular Immunization with Chimpanzee Adenovirus Vectored SARS-CoV-2 Vaccine Protects Against Pneumonia in Hamsters.

DNA vaccine protection against SARS-CoV-2 in rhesus macaques